UNSPSC 51161570: Nisbuterol mesilate or mesylate

This classification denotes an anti-asthmatic agent with the molecular formula C22H27NO6.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4ZSF6GBG5S, chemically known as benzoic acid, 4-methoxy-, 2-(acetyloxy)-4-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)phenyl ester, methanesulfonate (salt) but more generally known as nisbuterol mesylate, which bears US NIH Compound Identifier 3047792. Most nations, for tariff and trade purposes, schedule nisbuterol mesylate under HS 29225000.

As of Q4 2014, NISBUTEROL MESYLATE remains US FDA's Preferred Term for this commodity. Nisbuterol mesylate bears US NLM identifiers UMLS ID C2698474 and NCI Concept Code C75139. SMILES: CC(=O)OC1CC(CCC1OC(=O)C2CCC(CC2)OC)C(CNC(C)(C)C)O.CS(=O)(=O)O.

UNSPSC 51161570 Nisbuterol mesilate or mesylate is a Commodity code for pharmaceutical active ingredients and finished formulations. State and local governments procure bronchodilator medications under this code primarily through cooperative purchasing agreements that bundle generic multi-source pharmaceuticals with over-the-counter products for distribution across state agencies, local health departments, and other public health facilities. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, represents the primary issuing body active in this space, using cooperative vehicles to aggregate demand across participating states and streamline vendor contracting for pharmaceutical manufacturers and authorized wholesalers.

The most recent activity centers on Minnesota and participating states including Oregon. MMCAP issued an RFP (S1070000015802, due March 26, 2026) to establish multiple contracts for generic pharmaceuticals and OTC products, requiring vendors to certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain relationships with authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co., LLC), and accept a 3 percent administrative fee. Evaluation weights pricing competitiveness at 75 percent, with contract awards effective July 1, 2026, for a two-year initial term with optional extensions. Vendors must carry commercial general liability of $5,000,000 per occurrence and professional liability of $2,000,000, provide products with FDA compliance and minimum six-month shelf life, and submit pricing in multiple formats (flat price, net price, or WAC-minus structures) through the ePro procurement system.